This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Acalabrutinib is already approved to treat mantle cell lymphoma, but with BTD for CLL, that means it is one step closer to approval for our type of cancer and when approved, will then be easier for CLL patients to gain access and get it paid for.
Acalabrutinib is a potent next generation BTK inhibitor similar to the already approved powerful BTK inhibitor, ibrutinib (ibrutinib has radically improved outcomes in CLL), but acalabrutinib has a different and perhaps easier to tolerate side effect profile.
Here is the press release from AstraZeneca: https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia-14082019.html
This is good news for patients because it is good to have choices and acalabrutinib should be a strong option for many CLL patients.